EMA delays policy on clinical trial data transparency

By Zachary Brennan

- Last updated on GMT

The agency will wait until its October 2 board meeting to further clarify wording and practical arrangements
The agency will wait until its October 2 board meeting to further clarify wording and practical arrangements

Related tags: European union

The Management Board of the EMA (European Medicines Agency) has postponed the formal adoption of its policy on publication of clinical trial data, though the agency stopped short of revealing exactly why. 

The agency said it will wait until its October 2 meeting to further clarify wording and practical arrangements, though Board members “have confirmed their general support to the overall aims and objectives of the policy​,” including the more user-friendly amendments proposed by EMA Executive Director Guido Rasi that would allow data to be downloaded, saved or printed for academic and non-commercial research purposes.

Rasi’s recommendations represent an about face from the agency’s previous moves to keep data relatively restricted, which was previously a sticking point​ for the EU ombudsman.

The EMA in May seemed to be cowering to industry pressure and shifting away from increased transparency, saying that it would only allow data to be seen via an interface provided by the agency. But since then, the agency has investigated more user-friendly ways for users to view the data, which has drawn accusations from industry and the US Chamber of Commerce​ that the efforts might discourage pharma R&D.

The US CoC specifically took issue with the fact that commercially confidential information could not only go public in the EU, but also on an international level, which could spur copycats from foreign countries that seek to replicate the transparency efforts, the CoC contends.


This latest delay comes as the EMA’s Board “was not able to conclude on the final wording of the policy through a written procedure​.” Members of the Board have offered additional contributions which will now be considered and addressed in the next few weeks, the agency says.

The agency also acknowledges the complexity of the debate on both political and technical aspects which have emerged during the previous general and more targeted consultation phases. And over the last year, the EMA says it has tried to balance proactive data disclosure with the need to protect patient data and commercially confidential information.

The new clinical trial regulation will become applicable in 2016 at the earliest and will apply only to clinical trials conducted in the European Union.

The Agency will continue to work with the Management Board and the European Commission ahead of the 2 October meeting to ensure that members receive the clarifications requested and to facilitate the adoption of the policy​,” the EMA said.

Related news

Show more

Related products

show more

What’s Next for mRNA?

What’s Next for mRNA?

Catalent Pharma Solutions | 27-Jan-2022 | Insight Guide

Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many companies are looking beyond infectious...

SmartSignals Study Oversight

SmartSignals Study Oversight

Signant Health | 24-Jan-2022 | Product Brochure

Today, sponsors and study teams often struggle to support the growing variety and volume of clinical data. The right technology thought will help your...

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more